XORTX Historical Balance Sheet

XRTX Stock

USD 1.27 0.06 4.96%

Trend analysis of XORTX Therapeutics balance sheet accounts such as Total Assets of 5 M, Other Current Liab of 83.2 K, Total Current Liabilities of 280.2 K or Total Stockholder Equity of 3.1 M provides information on XORTX Therapeutics' total assets, liabilities, and equity, which is the actual value of XORTX Therapeutics to its prevalent stockholders. By breaking down trends over time using XORTX Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining XORTX Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether XORTX Therapeutics is a good buy for the upcoming year.

XORTX Therapeutics Inventory

(275,683)

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XORTX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.

About XORTX Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of XORTX Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. XORTX Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of XORTX Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which XORTX currently owns. An asset can also be divided into two categories, current and non-current.

XORTX Therapeutics Balance Sheet Chart

At this time, XORTX Therapeutics' Other Current Assets are fairly stable compared to the past year. Property Plant And Equipment Gross is likely to rise to about 144.8 K in 2024, whereas Total Assets are likely to drop slightly above 5 M in 2024.

Total Assets Other Current Liab Total Current Liabilities Accounts Payable Net Tangible Assets Capital Lease Obligations

Total Assets

Total assets refers to the total amount of XORTX Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in XORTX Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on XORTX Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of XORTX Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents XORTX Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of XORTX Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Capital Lease Obligations

XORTX Therapeutics capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to XORTX Therapeutics asset purchases. For example, XORTX Therapeutics can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as XORTX Therapeutics control over an asset for a big portion of its life. The total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee.

Most accounts from XORTX Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into XORTX Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XORTX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.At this time, XORTX Therapeutics' Other Current Assets are fairly stable compared to the past year. Property Plant And Equipment Gross is likely to rise to about 144.8 K in 2024, whereas Total Assets are likely to drop slightly above 5 M in 2024.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	3.8M	151.4K	87.6K	83.2K
Total Assets	17.3M	12.3M	5.5M	5.0M

Other Current Liab Total Assets

XORTX Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Short Long Term Debt Total	Short Term Debt	Intangible Assets	Net Tangible Assets	Non Currrent Assets Other	Other Assets	Long Term Debt	Non Current Liabilities Total	Deferred Long Term Liab	Net Invested Capital
Total Assets		0.73	0.82	0.98	-0.27	-0.99	-0.58	0.53	0.99	0.9	0.99	0.76	0.63	-0.25	0.89	1.0	-0.35	-0.43	-0.74	0.91	0.61	-0.62	0.56	0.95	-0.15	0.97
Other Current Liab	0.73		0.94	0.76	-0.41	-0.72	-0.1	0.12	0.72	0.47	0.72	0.17	0.15	-0.35	0.56	0.74	-0.09	-0.15	-0.28	0.58	0.42	-0.38	0.27	0.6	0.16	0.82
Total Current Liabilities	0.82	0.94		0.8	-0.51	-0.81	-0.24	0.44	0.81	0.6	0.81	0.35	0.24	-0.44	0.77	0.83	-0.09	-0.17	-0.34	0.62	0.54	-0.5	0.37	0.74	0.19	0.84
Total Stockholder Equity	0.98	0.76	0.8		-0.23	-0.98	-0.55	0.39	0.98	0.88	0.98	0.71	0.61	-0.19	0.8	0.98	-0.38	-0.45	-0.75	0.92	0.58	-0.58	0.56	0.9	-0.17	0.99
Property Plant And Equipment Net	-0.27	-0.41	-0.51	-0.23		0.2	0.45	-0.33	-0.21	-0.31	-0.21	-0.14	-0.35	-0.19	-0.31	-0.26	0.21	0.28	0.25	-0.31	-0.57	0.56	-0.52	-0.12	0.19	-0.29
Net Debt	-0.99	-0.72	-0.81	-0.98	0.2		0.51	-0.51	-1.0	-0.88	-1.0	-0.73	-0.57	0.28	-0.88	-0.99	0.31	0.38	0.7	-0.89	-0.54	0.54	-0.48	-0.96	0.12	-0.97
Retained Earnings	-0.58	-0.1	-0.24	-0.55	0.45	0.51		-0.49	-0.51	-0.76	-0.51	-0.82	-0.98	-0.44	-0.49	-0.55	0.7	0.77	0.86	-0.78	-0.79	0.84	-0.9	-0.45	0.71	-0.53
Accounts Payable	0.53	0.12	0.44	0.39	-0.33	-0.51	-0.49		0.51	0.55	0.51	0.67	0.38	-0.42	0.83	0.52	-0.15	-0.23	-0.3	0.33	0.57	-0.57	0.44	0.66	0.11	0.34
Cash	0.99	0.72	0.81	0.98	-0.21	-1.0	-0.51	0.51		0.88	1.0	0.73	0.57	-0.29	0.89	0.99	-0.3	-0.37	-0.7	0.88	0.53	-0.54	0.48	0.96	-0.11	0.97
Non Current Assets Total	0.9	0.47	0.6	0.88	-0.31	-0.88	-0.76	0.55	0.88		0.88	0.88	0.79	0.05	0.8	0.88	-0.4	-0.48	-0.87	0.92	0.61	-0.63	0.7	0.84	-0.34	0.85
Cash And Short Term Investments	0.99	0.72	0.81	0.98	-0.21	-1.0	-0.51	0.51	1.0	0.88		0.73	0.57	-0.29	0.89	0.99	-0.3	-0.37	-0.7	0.88	0.53	-0.54	0.48	0.96	-0.11	0.97
Net Receivables	0.76	0.17	0.35	0.71	-0.14	-0.73	-0.82	0.67	0.73	0.88	0.73		0.82	0.0	0.74	0.74	-0.59	-0.65	-0.78	0.78	0.7	-0.72	0.77	0.75	-0.35	0.65
Common Stock Shares Outstanding	0.63	0.15	0.24	0.61	-0.35	-0.57	-0.98	0.38	0.57	0.79	0.57	0.82		0.48	0.47	0.6	-0.7	-0.77	-0.91	0.85	0.73	-0.78	0.85	0.48	-0.78	0.6
Other Stockholder Equity	-0.25	-0.35	-0.44	-0.19	-0.19	0.28	-0.44	-0.42	-0.29	0.05	-0.29	0.0	0.48		-0.48	-0.28	-0.3	-0.3	-0.37	0.17	0.02	-0.08	0.29	-0.44	-0.84	-0.15
Total Liab	0.89	0.56	0.77	0.8	-0.31	-0.88	-0.49	0.83	0.89	0.8	0.89	0.74	0.47	-0.48		0.89	-0.18	-0.27	-0.54	0.68	0.58	-0.58	0.46	0.95	0.08	0.78
Total Current Assets	1.0	0.74	0.83	0.98	-0.26	-0.99	-0.55	0.52	0.99	0.88	0.99	0.74	0.6	-0.28	0.89		-0.35	-0.42	-0.71	0.89	0.61	-0.61	0.54	0.95	-0.13	0.97
Short Long Term Debt Total	-0.35	-0.09	-0.09	-0.38	0.21	0.31	0.7	-0.15	-0.3	-0.4	-0.3	-0.59	-0.7	-0.3	-0.18	-0.35		0.99	0.49	-0.53	-0.73	0.75	-0.77	-0.21	0.53	-0.36
Short Term Debt	-0.43	-0.15	-0.17	-0.45	0.28	0.38	0.77	-0.23	-0.37	-0.48	-0.37	-0.65	-0.77	-0.3	-0.27	-0.42	0.99		0.58	-0.61	-0.8	0.83	-0.84	-0.28	0.56	-0.43
Intangible Assets	-0.74	-0.28	-0.34	-0.75	0.25	0.7	0.86	-0.3	-0.7	-0.87	-0.7	-0.78	-0.91	-0.37	-0.54	-0.71	0.49	0.58		-0.91	-0.56	0.61	-0.71	-0.61	0.65	-0.73
Net Tangible Assets	0.91	0.58	0.62	0.92	-0.31	-0.89	-0.78	0.33	0.88	0.92	0.88	0.78	0.85	0.17	0.68	0.89	-0.53	-0.61	-0.91		0.65	-0.68	0.7	0.77	-0.53	0.92
Non Currrent Assets Other	0.61	0.42	0.54	0.58	-0.57	-0.54	-0.79	0.57	0.53	0.61	0.53	0.7	0.73	0.02	0.58	0.61	-0.73	-0.8	-0.56	0.65		-1.0	0.93	0.47	-0.31	0.58
Other Assets	-0.62	-0.38	-0.5	-0.58	0.56	0.54	0.84	-0.57	-0.54	-0.63	-0.54	-0.72	-0.78	-0.08	-0.58	-0.61	0.75	0.83	0.61	-0.68	-1.0		-0.94	-0.47	0.39	-0.58
Long Term Debt	0.56	0.27	0.37	0.56	-0.52	-0.48	-0.9	0.44	0.48	0.7	0.48	0.77	0.85	0.29	0.46	0.54	-0.77	-0.84	-0.71	0.7	0.93	-0.94		0.39	-0.48	0.54
Non Current Liabilities Total	0.95	0.6	0.74	0.9	-0.12	-0.96	-0.45	0.66	0.96	0.84	0.96	0.75	0.48	-0.44	0.95	0.95	-0.21	-0.28	-0.61	0.77	0.47	-0.47	0.39		0.02	0.87
Deferred Long Term Liab	-0.15	0.16	0.19	-0.17	0.19	0.12	0.71	0.11	-0.11	-0.34	-0.11	-0.35	-0.78	-0.84	0.08	-0.13	0.53	0.56	0.65	-0.53	-0.31	0.39	-0.48	0.02		-0.21
Net Invested Capital	0.97	0.82	0.84	0.99	-0.29	-0.97	-0.53	0.34	0.97	0.85	0.97	0.65	0.6	-0.15	0.78	0.97	-0.36	-0.43	-0.73	0.92	0.58	-0.58	0.54	0.87	-0.21

Click cells to compare fundamentals

XORTX Therapeutics Account Relationship Matchups

XORTX Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.1M	2.3M	17.3M	12.3M	5.5M	5.0M
Other Current Liab	641.5K	728.4K	3.8M	151.4K	87.6K	83.2K
Total Current Liabilities	1.3M	1.0M	4.2M	1.5M	294.9K	280.2K
Total Stockholder Equity	(211.7K)	1.3M	13.1M	7.0M	4.6M	3.1M
Property Plant And Equipment Net	731.0	341.0	0.0	92.5K	23.9K	28.8K
Net Debt	(7.8K)	(171.3K)	(14.8M)	(10.3M)	(3.4M)	(3.6M)
Retained Earnings	(6.8M)	(8.0M)	(7.6M)	(14.1M)	(17.9M)	(17.0M)
Accounts Payable	607.4K	305.8K	324.0K	1.3M	195.8K	186.0K
Cash	58.6K	171.3K	14.8M	10.4M	3.4M	3.6M
Non Current Assets Total	272.7K	234.3K	1.5M	1.5M	1.4M	731.9K
Cash And Short Term Investments	58.6K	171.3K	14.8M	10.4M	3.4M	3.6M
Net Receivables	15.5K	14.4K	40.7K	81.8K	60.7K	35.1K
Common Stock Shares Outstanding	595.5K	740.4K	1.1M	1.5M	2.0M	2.1M
Liabilities And Stockholders Equity	1.1M	2.3M	17.3M	12.3M	5.5M	5.0M
Other Stockholder Equity	683.0K	0.0	(1.4M)	(2.4M)	5.5M	5.8M
Total Liab	1.3M	1.0M	4.2M	5.4M	825.9K	784.6K
Total Current Assets	815.2K	2.1M	15.8M	10.9M	4.1M	4.2M
Short Long Term Debt Total	272.5K	43.3K	50.8K	77.4K	11.5K	10.9K
Intangible Assets	272.4K	234.3K	201.0K	199.4K	175.3K	189.0K
Net Tangible Assets	(484.1K)	1.0M	16.5M	9.2M	10.6M	11.1M
Net Invested Capital	(160.9K)	1.3M	16.7M	7.0M	4.6M	4.6M
Net Working Capital	(484.5K)	1.0M	14.9M	9.4M	3.8M	4.3M
Other Current Assets	741.2K	2.1M	1.0M	379.6K	560.4K	728.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

XORTX Historical Balance Sheet

XORTX Therapeutics Inventory

(275,683)

About XORTX Balance Sheet Analysis

XORTX Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Net Tangible Assets

Capital Lease Obligations

XORTX Therapeutics balance sheet Correlations

XORTX Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

XORTX Therapeutics balance sheet Accounts

Also Currently Popular

Additional Tools for XORTX Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Cash	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Net Invested Capital	+ 0.99	Total Stockholder Equity
Total Current Assets	+ 0.99	Cash

Other Assets	- 1.0	Non Currrent Assets Other
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Total Current Assets	- 0.99	Net Debt
Net Debt	- 0.99	Total Assets
Common Stock Shares Outstanding	- 0.98	Retained Earnings